Actively Recruiting
Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment
Led by UNC Lineberger Comprehensive Cancer Center · Updated on 2026-05-12
30
Participants Needed
2
Research Sites
141 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine if ctHPVDNA (circulating tumor HPV DNA) can be used as a non-invasive biomarker for identification and treatment monitoring of cervical cancer by characterizing correlation between plasma ctHPVDNA, urine transrenal HPVDNA (TrHPVDNA) levels and presence of cervical cancer at diagnosis and following definitive intent management.
CONDITIONS
Official Title
Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older on day of signing informed consent
- New diagnosis of cervical cancer
- Willing and able to comply with study procedures based on investigator judgment
You will not qualify if you...
- Women who are pregnant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Melissa Knutsen
Chapel Hill, North Carolina, United States, 27599
Actively Recruiting
2
Kamuzu Central Hospital
Lilongwe, Malawi
Not Yet Recruiting
Research Team
M
Melissa E Knutsen
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here